UCB's Global Corporate Website
Welcome to UCB in the United States
  • Healthcare Professionals
  • Patients
  • Investors

    • Categories

    Archives

    Dec

    18

    Charting the Future: UCB’s 2024 Achievements are Fueling our 2025 Ambitions

    Read More Share:linkedin| twitter| email

    Dec

    06

    UCB Presents New Data on Impact and Burden of Epilepsy at 2024 American Epilepsy Society (AES) Annual Meeting

    Read More Share:linkedin| twitter| email

    Nov

    26

    UCB presents latest scientific research in epilepsy at American Epilepsy Society (AES) Annual Meeting

    Read More Share:linkedin| twitter| email

    Nov

    20

    Closing gaps in HS care through community engagement and scientific innovation

    Read More Share:linkedin| twitter| email

    Nov

    20

    UCB Receives U.S. FDA Approval for BIMZELX® (bimekizumab-bkzx) as the First IL-17A and IL-17F Inhibitor for Adults with Moderate-to-Severe Hidradenitis Suppurativa

    Read More Share:linkedin| twitter| email

    Nov

    14

    New BIMZELX® (bimekizumab-bkzx) Data at ACR Convergence 2024 Highlights UCB’s Efforts to Deliver Differentiated Care for Patients with Psoriatic Arthritis and Axial Spondyloarthritis

    Read More Share:linkedin| twitter| email

    Nov

    14

    A Bright Future: Prioritizing Early Diagnosis, Maintenance, and Remissions in Rheumatology

    Read More Share:linkedin| twitter| email

    Oct

    15

    Powering the dreams of people impacted by myasthenia gravis (MG)

    Read More Share:linkedin| twitter| email

    Oct

    15

    UCB announces U.S. launch of UCB Myasthenia Gravis Scholarship™ for people impacted by myasthenia gravis in the U.S.

    Read More Share:linkedin| twitter| email

    Oct

    14

    UCB Receives U.S. FDA Approval for 320 mg Single-Injection Device Presentations of BIMZELX® (bimekizumab-bkzx)

    Read More Share:linkedin| twitter| email

    © 2009 - 2020 UCB, Inc., Atlanta. All rights reserved.
    USPR-CORP-0115-00003(2)